Please assess the completion status of the following clinical trial:

Trial Title: High-Flow in Hypercapnic Stable COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with COPD (FEV1/FVC \< 70%) and long term indication for home NIV for initiated at least 3 months prior the inclusion.~* Compliance with NIV (less than 5 hours and more than 1 hour) per night on average during the last 3 months prior to inclusion.~* Naïve to Nasal High Flow (NHF) therapy, i.e. having not used NHF in the last 6 months prior to inclusion.~* Able to understand, follow objectives and methods of protocol in French language.~* Patient affiliated to social security insurance or beneficiary of social health insurance.~* Willing and able to give written Informed Consent and to comply with the requirements of the study protocol.~Exclusion Criteria:~* Significant uncontrolled cardiac disease (investigator judgment), and/or Left Ventricular Ejection Fraction (LVEF) \< 45%.~* Known co-existing obstructive sleep apnea requiring expiratory pressure above 6 cmH20.~* Severe nasal obstruction, previous upper airway surgery preventing the usage of NHF, or, at the discretion of investigator, any other contraindication for using the NHF.~* Patients who are unable or unwilling to give informed consent.~* Participating in another research study.~* Patient protected by the Law, under guardianship or curators.~* Pregnancy and nursing mothers~* Patient not covered by a health insurance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Non Invasive Ventilation device group (Type: ACTIVE_COMPARATOR): The patients in the NIV arm will receive treatment as in their usual care with an additional educational session of one hour for improving compliance.
- Nasal High Flow (MyAirvo) device group (Type: EXPERIMENTAL): The patients in the NHF arm will receive NHF treatment and two hours training adaptation session will be conducted in the hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).